| Advice Pool |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Health and Fitness > Diabetes > Conquering Diabetes |
|
Advice Pool - Conquering Diabetes
One of the biggest and most common threats to living a long healthy life, diabetes, may have come up against it's match. According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product Ironically, the answer to fend off this disease is abundantly found within the human body. World-wide medical studies us ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ng adult stem cells derived from human bone marrow has shown absolutely exciting results. The April 11, 2007 issue of The lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. Times UK published an article entitled "Diabetics cured by Stem Cell treatment." This editorial focused on a breakthrou here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe h trial of fifteen young patients suffering from type 1 diabetes. The patients received transfusions of stem cell taken f d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro rom their own bodies. As reported in the Journal of the American Medical Association (JAMA), all but two volunteers in t ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc e trial do not need daily insulin injections up to three years after stopping their treatments. Another study with a easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi mazingly similar results comes from Brazil. In this trial thirteen patients between the ages of 14 -31, all with type 1 nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically iabetes, were treated intravenously with their own adult bone marrow stem cells. All but two of them are insulin free af and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ter undergoing the treatment. Interestingly, one of the two study subjects who did not make the insulin free group was in ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi fact insulin free for the first year after his treatment, but then relapsed. Type 2 Diabetes Research conducted at Tulan ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a e University found similar results with type 2 diabetes. In one study performed on rats who were injected with human adul dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod stem cells, within a short fours weeks demonstrated significant increase in their ability to produce insulin. In additio cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin n, these rats also showed an overall improvement in the pancreas and kidney functions.
Dr. Darwin J Prockop, dir tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ctor of Tulane University's Center for Gene Therapy drew some very positive conclusions from the fore mentioned research. t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel Dr Prockop believes these results suggest possible new treatments for people with diabetes, and especially for the 8 mil ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ion people in the United States alone whose worsening diabetes is causing kidney failure. Although science has not offic y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products ially found a cure to diabetes, research proves that the world is on the brink of a breakthrough. Adult stem cells derive . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de from the bone marrow have shown to be effective in the regeneration, restructuring and rejuvenation of organs that are e elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ffected by diabetes. This major advancement may be the missing key to eliminating this insidious disease once and for all tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:S-Corporations – State and Tax Issues You Will Be Spending Your Money Wisely When You Have Your Cards Designed and Professionally Printed Psychic Detectives and Psychic Investigations
|